(Reuters) -U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by strong sales of ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

The Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

The U.S. Senate Finance Committee could vote as soon as Tuesday on Robert F. Kennedy Jr.’s controversial nomination to be ...

When it comes to the potential of H5N1 avian flu, otherwise known as bird flu, picking up mutations that may lead to human-to ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Pfizer CEO Albert Bourla told investors he dined with RFK Jr, a vaccine skeptic and nominee to head HHS. They discussed ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...